Bevacizumab (Avastin) for Diabetic Macular Edema in Previously Vitrectomized Eyes  

Oleh:

Yanyali, Ates ; Aytug, Banu ; Horozoglu, Fatih ; Nohutcu, Ahmet F.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: American Journal of Ophthalmology (keterangan: ada di ClinicalKey) vol. 144 no. 01 (Jul. 2007), page 124.

Ketersediaan

Perpustakaan FK Nomor Panggil: A12.K.2007.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Purpose To report the visual acuity (VA) and foveal thickness (FT) changes after intravitreal bevacizumab for diabetic macular edema (DME) in previously vitrectomized eyes. Design Retrospective, noncomparative, interventional case series. Methods Medical records of 11 eyes of 10 patients who underwent intravitreal bevacizumab injection for persistent DME were reviewed. This retrospective study included eyes that had persistent DME despite prior pars plana vitrectomy with internal limiting membrane removal at our institution with optical coherence tomography (OCT) assessment of DME. All eyes received three intravitreal injections of bevacizumab 1.25 mg/0.05 ml monthly. Results Mean FT was 408 ± 77 µm at baseline, 453 ± 97 µm at three months, and 454 ± 101 µm at six months (P = .172). Mean Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores were 59 ± 15 (20/80) at baseline, 59 ± 16 (20/80) at three months, 57 ± 15 (20/80) at six months (P = .398). Conclusion No change in VA and FT was observed in the short-term after intravitreal bevacizumab for DME in previously vitrectomized eyes.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali